‘Small molecules are sexy again’: Gate Bioscience debuts with $60M and a new way to stop disease-causing proteins
Gate Bioscience has raised $60 million to develop a new type of pill-based medicine — which it calls a molecular gate — that can go after the spectrum of malicious proteins.
The Brisbane, CA biotech was started in 2021 by Jordi Mata‐Fink, a member of the founding team for Generate:Biomedicines and now Gate’s CEO; Pat Sharp, whose postdoc work serves as the foundation for the company’s platform; and Raman Talwar, a former senior associate at Flagship Pioneering. The Series A round was led by Versant Ventures and Andreessen Horowitz (a16z), and investors also included ARCH Venture Partners and GV, Google’s venture arm.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.